Bills › 91st General Assembly
Relating to nonopioid drugs on the medical assistance preferred drug list, and health carriers’ development of a pain management access plan
Topics:Health careFentanyl & drug crimesMedicaid
Same legislation: HSB 151
Where it is now
- Done: IntroducedFebruary 20, 2025
- Done: SubcommitteeFebruary 20, 2025
- Stopped: Senate committeeDied when the General Assembly ended
- Next: Passes the Senate
- Next: House committeeFunnel: by March 20, 2026
- Next: Passes the House
- Next: To the Governor
- Next: Signed into law
Died when the session ended The General Assembly adjourned on October 2, 2026. Bills that didn’t pass both chambers died. What’s a funnel?
What’s in it
This bill relates to nonopioid drugs on the medical assistance preferred drug list, and health carriers’ development of a pain management access plan. _____ for an opioid or narcotic drug for the treatment or management of pain on the preferred drug list. Impermissible disadvantaging or discouragement of a nonopioid drug includes designating the nonopioid drug as a nonpreferred drug if any opioid or narcotic is designated as a preferred drug, and establishing more restrictive or extensive utilization controls for a nonopioid drug than the least restrictive or extensive utilization controls applicable to an opioid or narcotic drug.
Read the full explanation
The bill applies to a nonopioid drug immediately upon its approval by the FDA for the treatment or management of pain, regardless of whether the drug has been reviewed by the medical assistance pharmaceutical and therapeutics committee for inclusion on the preferred drug list. The bill also applies to drugs being provided under a contract between the department and a Medicaid managed care organization. Under the bill, a health carrier shall develop and implement a pain management access plan (plan). “Pain management access plan” and “pain management alternatives” are defined in the bill. A plan shall provide coverage for a minimum of two alternative prescription medication treatment options that are approved by the FDA for the treatment of pain, and that are not schedule I, II, or III controlled substances; and provide coverage for a minimum of three alternative nonpharmacologic treatment modalities. A health carrier’s plan shall not establish utilization controls for clinically appropriate nonopioid drugs or drug products approved by the FDA that are more restrictive or extensive than the least restrictive or extensive utilization controls applicable to an opioid or narcotic drug. A health carrier shall file the plan with the insurance division for approval. _____ preferential coverage of, and access to, opioid drugs. A health carrier shall annually distribute educational materials to providers within the health carrier’s network, and to covered persons, about the health carrier’s plan, and shall make the plan publicly available on the health carrier’s internet site. The commissioner of insurance may adopt rules to administer the bill.
From the explanation printed with the bill as introduced, written by the Legislative Services Agency. Amendments adopted later aren’t reflected. Full bill text
Senate subcommittee
Named March 3, 2025. On March 4, 2025 it recommended amendment and passage.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Iowa Code it changes
Creates§505.36
Amends§249A.20A
Read from the bill as introduced. Each links to every bill touching that chapter of the Iowa Code. How the Code works
Lobbying
6 for · 2 against · 9 undecided · Who →
Family tree
Where this legislation came from and where it went: earlier tries, the versions it moved through this Assembly, and later bills built on it.
91st General Assembly
Earlier and later bills are matched by wording or an identical title; check the text to be sure it’s the same idea.